Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis

BMC Neurology

Table 1 General clinical characteristics

	MG (n = 89)	HC (n = 43)	P value
Age (mean ± SD)	58.34 ± 14.99	55.72 ± 19.51	0.94
Sex (male/female)	44/45	27/16	0.18
Onset age	55.36 ± 15.20
EOMG	28
LOMG	61
AChR-Ab ( +)	81
MuSK-Ab ( +)	1
AChR-Ab/MuSK-Ab (-)	7
OMG	38
GMG	51
Thymoma	22
Thymic hyperplasia	3
Acute aggravation state	42
OMG	14
GMG	28
MGFA-I	14
MGFA-II	10
MGFA-III	14
MGFA-IV	3
MGFA-V	0
MMS^a	58
Immunotherapy
Tacrolimus only	13
Corticosteroid only	19
Azathioprine only	1
Cyclophosphamide only	1
Tacrolimus and corticosteroid	11
Azathioprine and corticosteroid	2

Abbreviations: MG Myasthenia gravis, HC Healthy control, n Number, EMOG Early-onset myasthenia gravis, LOMG Late-onset myasthenia gravis, AChR-Ab Acetylcholine receptor-specific antibody, MuSK-Ab Muscle-specific kinase-specific antibody, OMG Ocular myasthenia gravis, GMG Generalized myasthenia gravis, MGFA MG Foundation of America, MMS Minimal manifestation status
^aMMS: fifty-eight MG patients were enrolled who achieved the minimal manifestation state (MMS) after treatment, including 47 patients with MMS at enrollment and 11 patients who achieved MMS at follow-up

ISSN: 1471-2377